Collateral for a security interest recorded Jun 26, 2026 (JPMorgan Chase Bank, N.A.).
Term ends Dec 20, 2026 · Low confidence
20-year base term ends Dec 20, 2026
Held by Soleno Therapeutics, Inc.
Filed May 27, 2021 as application 17/332,878 · Granted Oct 17, 2023
Base term plus 243 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2006
2026
Clock starts
Dec 20, 2006
Dec 20, 2006
Term ends
Dec 20, 2026
Dec 20, 2026
Granted
Oct 17, 2023
Oct 17, 2023
base term
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
243
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,085,998, US 11,045,478, US 7,572,789, US 7,799,777, US 9,381,202.
None due
Maintenance fees
This term ends before the first maintenance fee's grace period does, 4 years from grant, so no fee can end it early.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 243 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. No maintenance fee can end this term early. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 20, 2006, when application 11/614,044, the earliest non-provisional in its chain, was filed (this one was filed May 27, 2021); a parent in its chain could not be resolved (the next row) | Dec 20, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +243 days, USPTO patent term adjustment record | Aug 20, 2027 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,085,998, US 11,045,478, US 7,572,789, US 7,799,777, US 9,381,202) | capped to Dec 20, 2026 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No maintenance fee can end the term early | In force | High confidence |
| Computed term end | The steps above, in order | Dec 20, 2026 | Low confidence |
This family
| US 7,799,777 | In force Mar 2029 | Mar 2029 |
| US 7,572,789 | In force no later than Dec 2026 | no later than Dec 2026 |
| Application 12/819,155 | Abandoned not computed | not computed |
| US 9,381,202 | In force Jul 2027 | Jul 2027 |
| US 10,085,998 | In force Dec 2026 | Dec 2026 |
| Application 16/110,621 | Abandoned not computed | not computed |
| US 11,045,478 | In force Dec 2026 | Dec 2026 |
| US 11,786,536 | this patent Dec 2026 | Dec 2026 |
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 15, 2021 Reel 56554, frame 29 | Cowen, Neil M.; Kashkin, Kenneth B.; Yamout, Khaled A. | Essentialis, Inc. | Assignment of Assignor's Interest |
| Dec 17, 2024 Reel 69613, frame 369 | Soleno Therapeutics, Inc.; Essentialis, Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Mar 12, 2025 Reel 70494, frame 42 | Soleno Therapeutics, Inc.; Essentialis, Inc. | Oxford Finance LLC, as Collateral Agent | Amended and Restated Intellectual Property Security Agreement |
| Dec 3, 2025 Reel 73832, frame 312 | Essentialis, Inc. | Soleno Therapeutics, Inc. | Assignment of Assignor's Interest |
| May 19, 2026 Reel 75778, frame 94 | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc.; Essentialis, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| May 19, 2026 Reel 75601, frame 687 | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc.; Essentialis, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Essentialis, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Essentialis, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| Jun 26, 2026 Reel 75106, frame 487 | Soleno Therapeutics, Inc. | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2026
Term ends Dec 20, 2026. No further fees fall due before then
Note
The 243 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,085,998, US 11,045,478, US 7,572,789, US 7,799,777, US 9,381,202.
Citations
4
later US patents cite this one
That is top 25% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.